Apr 11 |
Indaptus Therapeutics Presents Positive Mechanism of Action Data at the American Association for Cancer Research Annual Meeting
|
Mar 28 |
Indaptus Therapeutics to Present at the MedInvest Biotech and Pharma Investor Conference
|
Mar 18 |
Indaptus Therapeutics to Participate in Tribe Public Webinar On Wednesday, March 20, 2024
|
Mar 13 |
Indaptus Therapeutics Reports Fourth Quarter and Year-End 2023 Financial Results and Provides Corporate Update
|
Mar 4 |
Indaptus Therapeutics Announces Positive Results from Second Cohort of Phase 1 Trial; Company Initiates Multi-Dose Cohort
|
Feb 29 |
Why Butterfly Network Shares Are Trading Lower By 22%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
|
Feb 8 |
Indaptus Therapeutics Expands Digital Presence with Launch of Social Media Channels
|
Jan 4 |
European Patent Office Approves Key Patent for Indaptus Therapeutics’ Platform Technology
|
Nov 6 |
Indaptus Therapeutics GAAP EPS of -$0.47 beats by $0.05
|
Nov 6 |
Indaptus Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Update
|